Switch to plant-based diet could boost prostate cancer survival

by Steven ReinbergFollowing a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a new study suggests.Men who ate adiet&nbs

Oncology December 22,2023

Switch to plant-based diet could boost prostate cancer survival

by Steven ReinbergFollowing a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a new study suggests.Men who ate adiet&nbs

Oncology December 22,2023

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Oncology December 22,2023

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh

Oncology December 22,2023

Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

byTel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study conducted at Tel Aviv University has determined that use of the Inquiry Based Stress Reduction (IBSR) technique among women with

Oncology December 22,2023

Improving emotional well-being, quality of sleep, and decision making in patients at risk for breast cancer

byTel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study conducted at Tel Aviv University has determined that use of the Inquiry Based Stress Reduction (IBSR) technique among women with

Oncology December 22,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Oncology December 22,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Oncology December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Oncology December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Oncology December 22,2023

Improving drug therapy for relapsed leukemia

by Haleigh Ehmsen,Northwestern UniversityResponse rates in all FLT3mutpatients treated at any dose (n = 56) and in those who did (n = 35) or did not (n = 21) receive prior treatment with a

Oncology December 22,2023

Improving drug therapy for relapsed leukemia

by Haleigh Ehmsen,Northwestern UniversityResponse rates in all FLT3mutpatients treated at any dose (n = 56) and in those who did (n = 35) or did not (n = 21) receive prior treatment with a

Oncology December 22,2023

Breast-conserving treatment without surgery not supported at this time

by NRG OncologyResults from NRG Oncology's BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radio

Oncology December 22,2023

Breast-conserving treatment without surgery not supported at this time

by NRG OncologyResults from NRG Oncology's BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radio

Oncology December 22,2023

Improving melanoma diagnostic tools

by QIMR Berghofer Medical Research InstituteAge-standardized melanoma incidence from 1982 through 2018 in the U.S. White, Queensland, and Scotland populations. Joinpoint regression models for in situ

Oncology December 22,2023

Improving melanoma diagnostic tools

by QIMR Berghofer Medical Research InstituteAge-standardized melanoma incidence from 1982 through 2018 in the U.S. White, Queensland, and Scotland populations. Joinpoint regression models for in situ

Oncology December 22,2023

Study offers a potential strategy to improve T cell therapy in solid tumors

byPerelman School of Medicine at the University of PennsylvaniaRegnase-1 and Roquin-1 double knockout alters the activation profile of resting engineered T cells. (A) Healthy human donor T cells

Oncology December 22,2023

Study offers a potential strategy to improve T cell therapy in solid tumors

byPerelman School of Medicine at the University of PennsylvaniaRegnase-1 and Roquin-1 double knockout alters the activation profile of resting engineered T cells. (A) Healthy human donor T cells

Oncology December 22,2023

Cancer study may accidentally help researchers create usable blood stem cells

by Garth Sundem,CU Anschutz Medical CampusBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaA massive research effort over more than a quarter

Oncology December 22,2023

Cancer study may accidentally help researchers create usable blood stem cells

by Garth Sundem,CU Anschutz Medical CampusBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaA massive research effort over more than a quarter

Oncology December 22,2023